Ignite Creation Date:
2024-05-06 @ 9:55 AM
Last Modification Date:
2024-10-26 @ 12:22 PM
Study NCT ID:
NCT03114683
Status:
COMPLETED
Last Update Posted:
2020-12-07
First Post:
2017-04-04
Brief Title:
Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With RelapsedRefractory Classical Hodgkins Lymphoma
Sponsor:
Innovent Biologics Suzhou Co Ltd
Organization:
Innovent Biologics Suzhou Co Ltd
Organization Data
Organization:
Innovent Biologics Suzhou Co Ltd
Class:
INDUSTRY
Study ID:
CIBI308B201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Innovent Biologics Suzhou Co Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None